Clinical Report: Vericiguat's Effects on Acute Coronary Syndrome Patients

Overview

The EVE-ACSrEF trial investigates the efficacy of vericiguat in patients with acute coronary syndrome (ACS) and heart failure with reduced ejection fraction (HFrEF). The study aims to determine if adding vericiguat to guideline-directed medical therapy (GDMT) can reduce cardiovascular death and heart failure hospitalizations.

Background

Heart failure is a leading cause of morbidity and mortality, particularly in patients with coronary artery disease. Acute coronary syndrome, a critical manifestation of coronary artery disease, poses significant risks for patients with HFrEF. Current treatment strategies aim to improve outcomes, but there remains a need for novel therapies like vericiguat to enhance patient care.

Data Highlights

No numerical data available in the provided source material.

Key Findings

• Vericiguat is a soluble guanylate cyclase stimulator that enhances the NO-sGC-cGMP signaling pathway.
• The EVE-ACSrEF study evaluates vericiguat's efficacy in ACS patients with HFrEF (LVEF < 45%).
• Current guidelines recommend comprehensive GDMT for managing ACS and HFrEF.
• Vericiguat has shown benefits in reducing cardiovascular death and heart failure hospitalizations in other trials.
• Patients with ACS and HFrEF remain at high risk for adverse outcomes despite existing therapies.

Clinical Implications

The findings from the EVE-ACSrEF trial may support the integration of vericiguat into treatment regimens for ACS patients with HFrEF. Clinicians should consider the potential benefits of adding vericiguat to GDMT to improve patient outcomes.

Conclusion

The EVE-ACSrEF trial aims to clarify the role of vericiguat in managing ACS patients with HFrEF, potentially leading to improved clinical strategies for this high-risk population.

References

1. Vericiguat in patients with acute coronary syndrome and reduced ejection fraction: the EVE-ACSrEF study | BMC Cardiovascular Disorders | Springer Nature Link, 2024 -- Vericiguat in patients with acute coronary syndrome and reduced ejection fraction: the EVE-ACSrEF study
2. 2025 Guideline for Acute Coronary Syndromes - Professional Heart Daily | American Heart Association, 2025 -- 2025 Guideline for Acute Coronary Syndromes
3. Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction - American College of Cardiology, 2020 -- VICTORIA
4. Clinical Research in Cardiology — The Importance of Prompt and Personalized Management of Heart Failure: A Call for Integration into Updated Guidelines
5. European Journal of Preventive Cardiology — Safety of beta-blocker discontinuation after acute coronary syndromes with preserved or mildly reduced left ventricular ejection fraction: a target trial emulation from a real-world cohort
6. Clinical Research in Cardiology — Impact of sacubitril/valsartan on cardiac structural changes in comparison to other renin-angiotensin system blockers: a difference-in-difference analysis using propensity-score matched cohorts
7. Basic Research in Cardiology — Impact of Ventricular Fibrillation on Infarct Size Following Myocardial Infarction: A Translational Investigation
8. 2025 Guideline for Acute Coronary Syndromes - Professional Heart Daily | American Heart Association
9. Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction - American College of Cardiology
10. Vericiguat in patients with acute coronary syndrome and reduced ejection fraction: the EVE-ACSrEF study | BMC Cardiovascular Disorders | Springer Nature Link